Amsterdam-based Agendia, a molecular diagnostics company, has raised $34 million in its fourth venture round, adding ING to its list of backers. Current investors Van Herk Biotech, Gilde Healthcare Partners and Global Life Science Ventures also participated. The company developed the MammaPrint, a prognostic DNA microarray-based in vitro diagnostic test that measures the activity of 70 genes to assess the risk of breast cancer recurrence.
-Â check out the release on the latest round
Related Article:
Personalized medicine advances with Agendia's new genetic test. Report
Diagnostics tied to new drugs. Report